Ready to crush your New Year’s health goals? These breakthrough medications offer more than weight loss—they support your ...
Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand version in early 2025 Charlotte Phillipp is a Weekend Writer-Reporter at ...
Zepbound is a prescription injectable medication that’s used for weight loss. You or a caregiver can administer it as a subcutaneous injection into your stomach or thigh. A caregiver can also ...
Compounding can include adding extra ingredients, removing ingredients, or using different strengths of ingredients ... in ...
Since Zepbound was approved by the FDA to treat obesity in late 2023, its maker Eli Lilly has been steadily closing in on fierce rival Novo Nordisk’s early lead in the obesity market.
According to a new report, however, a competitor may be stealing the spotlight in 2025. GlobaData issued a report stating that it expects Eli Lilly’s Zepbound to lead the obesity market in the coming ...
Tirzepatide, the drug ingredient contained in both Mounjaro and Zepbound, has been in shortage ... although Novo recently reported all dose strengths of semaglutide are now available.